283 related articles for article (PubMed ID: 34400305)
1. Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
Shen N; Yang C; Zhang X; Tang Z; Chen X
Acta Biomater; 2021 Nov; 135():543-555. PubMed ID: 34400305
[TBL] [Abstract][Full Text] [Related]
2. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy.
Wang Y; Shen N; Wang Y; Li M; Zhang W; Fan L; Liu L; Tang Z; Chen X
Biomater Sci; 2021 Apr; 9(8):3019-3027. PubMed ID: 33656040
[TBL] [Abstract][Full Text] [Related]
5. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.
Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z
J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
[TBL] [Abstract][Full Text] [Related]
8. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC
Zhang J; Larrocha PS; Zhang B; Wainwright D; Dhar P; Wu JD
J Immunother Cancer; 2019 Aug; 7(1):223. PubMed ID: 31446896
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
11. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
12. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles.
Pham LM; Poudel K; Ou W; Phung CD; Nguyen HT; Nguyen BL; Karmacharya P; Pandit M; Chang JH; Jeong JH; Ku SK; Yong CS; Choi HG; Kim JO
Int J Pharm; 2021 Aug; 605():120816. PubMed ID: 34161810
[TBL] [Abstract][Full Text] [Related]
13. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
14. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
16. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
Wang X; Li X; Ito A; Sogo Y; Ohno T
Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
[TBL] [Abstract][Full Text] [Related]
18. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.
Ou DL; Lin YY; Hsu CL; Lin YY; Chen CW; Yu JS; Miaw SC; Hsu PN; Cheng AL; Hsu C
Liver Cancer; 2019 May; 8(3):155-171. PubMed ID: 31192153
[TBL] [Abstract][Full Text] [Related]
19. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM
Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249
[No Abstract] [Full Text] [Related]
20. Cisplatin-induced Pyroptosis Enhances the Efficacy of PD-L1 Inhibitor in Small-Cell Lung Cancer via GSDME/IL12/CD4Tem Axis.
Xuzhang W; Lu T; Jin W; Yu Y; Li Z; Shen L; Niu X; Ai X; Xia L; Lu S
Int J Biol Sci; 2024; 20(2):537-553. PubMed ID: 38169676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
